Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023)

Vaxcyte (PCVX) has 2 years of Other Operating Expenses data on record, last reported at $75.0 million in Q4 2023.

  • On a quarterly basis, Other Operating Expenses rose 226.16% to $75.0 million in Q4 2023 year-over-year; TTM through Sep 2024 was $75.0 million, a 226.16% increase, with the full-year FY2023 number at $75.0 million, up 226.16% from a year prior.
  • Other Operating Expenses reached $75.0 million in Q4 2023 per PCVX's latest filing, up from $23.0 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for PCVX hit a ceiling of $75.0 million in Q4 2023 and a floor of $23.0 million in Q4 2022.